5-Fluorouracil treatment of problematic scars

Plastic and Reconstructive Surgery

Volumn 123, Issue 1, 2009, Pages 139-148

  Haurani, Mounir J ^a   Foreman, Kenneth ^a   Yang, James J ^a   Siddiqui, Aamir ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUOROURACIL; LIDOCAINE; SILICONE; ANTIMETABOLITE;

ADULT; ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG TREATMENT FAILURE; EXCISION; FEMALE; FOLLOW UP; HUMAN; HYPERTROPHIC SCAR; KELOID; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT DISEASE; TREATMENT RESPONSE; WOUND; DISEASE COURSE; HOSPITALIZATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTIMETABOLITES; CICATRIX, HYPERTROPHIC; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KELOID; MALE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 60549093564     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181904d1b     Document Type: Article

References (35)

1. Nakaoka H, Miyauchi S, Miki Y. Proliferating activity of dermal fibroblasts in keloids and hypertrophic scars. Acta Derm Venereol. 1995;75:102-104.
2. Luo S, Benathan M, Raffoul W, Panizzon RG, Egloff DV. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg. 2001;107:87-96.
3. Al-Attar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006; 117:286-300.
4. Wang Z, Fong KD, Phan T-T, Lim IJ, Longaker MT, Yang GP. Increased transcriptional response to mechanical strain in keloid fibroblasts due to increased focal adhesion complex formation. J Cell Physiol. 2006;206:510-517.
5. Campaner AB, Ferreira LM, Gragnani A, Bruder JM, Cusick JL, Morgan JR. Upregulation of TGF-beta1 expression may be necessary but is not sufficient for excessive scarring. J Invest Dermatol. 2006;126:1168-1176.
6. Younai S, Nichter LS, Wellisz T, Reinisch J, Nimni ME, Tuan TL. Modulation ofcollagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts. Ann Plast Surg. 1994;33:148-151.
7. Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg. 1996;98:827-833.
8. Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg. 1999;25:224-232.
9. Uppal RS, Khan U, Kakar S, Talas G, Chapman P, McGrouther AD. The effects of a single dose of 5-fluorouracil on keloid scars: A clinical trial of timed wound irrigation after extralesional excision. Plast Reconstr Surg. 2001;108:1218-1224.
10. Gupta S, Kalra A. Efficacy and safety of intralesional 5-flu-orouracil in the treatment of keloids. Dermatology. 2002;204: 130-132.
11. Apikian M, Goodman G. Intralesional 5-fluorouracil in the treatment of keloid scars. Australas J Dermatol. 2004;45:140-143.
12. Manuskiatti W, Fitzpatrick RE. Treatment response of keloi-dal and hypertrophic sternotomy scars: Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol. 2002;138:1149-1155.
13. Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, et al. Intralesional 5-fluorouracil in the treatment of keloids: An open clinical and histopathologic study. J Am Acad Dermatol. 2005;52:474-479.
14. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 8. Adjuvant systemic therapy for women with node-positive breast cancer. CMAJ. 1998;158:S52-S64.
15. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 8. Adjuvant systemic therapy for women with node-negative breast cancer. CMAJ. 1998;158:S43-S51.
16. Macdonald JS. Adjuvant therapy of colon cancer. CA Cancer J Clin. 1999;49:202-219.
17. Brentjens R, Saltz L. Islet cell tumors of the pancreas: The medical oncologist's perspective. Surg Clin North Am. 2001; 81:527-542.
18. Sedrakyan A, van der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2004;128:414-419.
19. Bulstrode NW, Mudera V, McGrouther DA, Grobbelaar AO, Cambrey AD. 5-Fluorouracil selectively inhibits collagen synthesis. Plast Reconstr Surg. 2005;116:209-221; discussion 222-223.
20. Kelly AP. Medical and surgical therapies for keloids. Dermatol Ther. 2004;17:212-218.
21. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: A review with a critical look at therapeutic options. J Am Acad Dermatol. 2002;46:S63-S97.
22. Draaijers LJ, Tempelman FRH, Botman YAM, et al. The patient and observer scar assessment scale: A reliable and feasible tool for scar evaluation. Plast Reconstr Surg. 2004; 113:1960-1965, discussion 1966-1967.
23. van de Kar AL, Corion LUM, Smeulders MJC, Draaijers LJ, van der Horst CM, van Zuijlen PP. Reliable and feasible evaluation of linear scars by the Patient and Observer Scar Assessment Scale. Plast Reconstr Surg. 2005;116:514-522.
24. Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg. 2001;27:23-27.
25. Ahn ST, Monafo WW, Mustoe TA. Topical silicone gel for the prevention and treatment of hypertrophic scar. Arch Surg. 1991;126:499-504.
26. Clinical Policy/Procedure Patient Care Services, H.F.H.D.M. Chemo: Chemotherapy/Cytotoxic Drug Administration, 1994.
27. Parkell, Inc. F.N. Product Information Sheet for Blu-Mousse, 2001.
28. Kummar S, Noronha V. Pharmacology of cancer chemotherapy: Antimetabolites. In Devita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Vol. 2. Philadelphia: Lippincott Williams & Wilkins; 2000:362-365.
29. Kufe DW, Frei E III, Holland JF, et al. Holland Frei Cancer Medicine. 7th Ed. Columbia: B.C. Decker; 2006.
30. Taylor B, McGrouther DA, Bayat A. Use of a non-contact 3D digitiser to measure the volume of keloid scars: A useful tool for scar assessment. J Plast Reconstr Aesthet Surg. 2007; 60:87-94.
31. Mustoe TA, Cooter RD, Gold MH, etal. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110:560-571.
32. Chowdri NA, Masarat M, Mattoo A, Darzi MA. Keloids and hypertrophic scars: Results with intraoperative and serial postoperative corticosteroid injection therapy. Aust N Z J Surg. 1999;69:655-659.
33. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol. 1997;37:755-757.
34. Sclafani AP, Gordon L, Chadha M, Romo T III. Prevention of earlobe keloid recurrence with postoperative corticoste-roid injections versus radiation therapy: A randomized, prospective study and review of the literature. Dermatol Surg. 1996;22:569-574.
35. Atiyeh BS, Costagliola M, Hayek SN. Keloid of hypertrophic scar: The controversy. Review of the literature. Ann Plast Surg. 2005;54: 676-680.